Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Marquest Medical

This article was originally published in The Gray Sheet

Executive Summary

Will shut down its Nogales, Mexico operations and integrate them into its central manufacturing facility in Englewood, Colorado. FDA cited the Mexican plant for GMP violations last July ("The Gray Sheet" Nov. 16, 1992, p. 5). The consolidation is part of a broad restructuring effort, which also included the sale of Marquest's Parker, Colorado facility in January and ongoing financing negotiations with Scherer Healthcare ("The Gray Sheet" Jan. 18, p. 15). The restructuring was undertaken to finance costs associated with an October 1991 consent decree that required the firm to cease U.S. operations until it could demonstrate compliance with GMPs. The revalidation and product reintroduction process "is now essentially complete," Marquest says.
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT000298

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel